Payment overview · 2025
General Payments
$1,146.38
59 reported records · 16 companies
Healthcare provider profile · identity verified
Aurora B Madanguit, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · COLOMA, MI · NPI 1619902855
Verified facts
What the public records show
CMS Open Payments records show Aurora B Madanguit, MD received $1,146.38 in general payments during 2025 across 59 reported records.
Vanda Pharmaceuticals Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $184.16 | 16.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.59 | 11.7% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $123.17 | 10.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.38 | 8.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $96.64 | 8.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.74 | 7.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.56 | 7.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.09 | 4.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.81 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.49 | 4.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.94 | 3.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.01 | 3.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.59 | 3.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.12 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.79 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.30 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,146.38 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $184.16 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.59 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123.17 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $97.38 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $96.64 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $83.56 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.69 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $53.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.49 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 23 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 695 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 150 |
| Alprazolam | Alprazolam | 403 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 90 |
| Lisinopril | Lisinopril | 282 | 83 |
| Gabapentin | Gabapentin | 281 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 71 |
| Losartan Potassium | Losartan Potassium | 182 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 58 |
| Omeprazole | Omeprazole | 162 | 49 |
| Tramadol Hcl | Tramadol Hcl | 158 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 149 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 52 |
| Furosemide | Furosemide | 144 | 51 |
| Pregabalin | Pregabalin | 129 | 19 |
| Potassium Chloride | Potassium Chloride | 125 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 40 |
| Allopurinol | Allopurinol | 107 | 32 |
| Prednisone | Prednisone | 106 | 66 |
| Trazodone Hcl | Trazodone Hcl | 106 | 28 |
| Simvastatin | Simvastatin | 101 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 14 |
| Carvedilol | Carvedilol | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 31 |
| Azithromycin | Azithromycin | 95 | 61 |
| Eliquis | Apixaban | 91 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 46 |
| Metformin Hcl | Metformin Hcl | 80 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 29 |
| Sertraline Hcl | Sertraline Hcl | 80 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 18 |
| Glimepiride | Glimepiride | 77 | 25 |
| Ozempic | Semaglutide | 77 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 14 |
| Meloxicam | Meloxicam | 66 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 20 |
| Mirtazapine | Mirtazapine | 61 | 21 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Torsemide | Torsemide | 58 | 19 |
| Montelukast Sodium | Montelukast Sodium | 57 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 23 |
| Jardiance | Empagliflozin | 55 | 23 |
| Fluconazole | Fluconazole | 53 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 36 |
| Ibuprofen | Ibuprofen | 49 | 22 |
| Celecoxib | Celecoxib | 48 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Famotidine | Famotidine | 48 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Cephalexin | Cephalexin | 42 | 33 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 14 |
| Amoxicillin | Amoxicillin | 35 | 25 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Estradiol | Estradiol | 34 | 13 |
| Methocarbamol | Methocarbamol | 34 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 12 |
| Nystatin | Nystatin | 31 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 13 |
| Diazepam | Diazepam | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Fentanyl | Fentanyl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Temazepam | Temazepam | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,146.38 · 59 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, Auvelity, CAPLYTA, ELIQUIS, ENTRESTO, FANAPT, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, Wegovy, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error